Evodenoson is a selective agonist of the A2A adenosine receptor, used for its anti-inflammatory effects, including reducing intestinal fluid secretion, edema, tissue injury, and neutrophil infiltration induced by Clostridium difficile toxin A; this protective effect is mediated through the reduction of myeloperoxidase (MPO) and adenosine deaminase (ADA) activity and the suppression of tumor necrosis factor-alpha (TNF-α) production.